Therapeutic Development in Charcot Marie Tooth Type 1 Disease

Area of Science:

• Neurology
• Genetics
• Biomedical Research

Background:

• Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy.
• CMT is primarily classified into demyelinating (CMT1) and axonal (CMT2) forms, with CMT1 being more prevalent.
• Recent years have seen a significant increase in research publications focusing on CMT1 subtypes.

Purpose of the Study:

• To review cellular and animal models of CMT1 that offer potential therapeutic strategies.
• To explore emerging therapeutic avenues, including ongoing clinical trials for CMT1.
• To discuss key considerations for the development of regulatory-approved therapies for CMT1.

Main Methods:

• Systematic review of published literature on CMT1 cellular and animal models.
• Analysis of data from preclinical studies and clinical trials.
• Discussion of challenges in therapeutic development for CMT1.

Main Results:

• A notable rise in CMT1 research publications since the year 2000.
• Identification of various cellular and animal models providing insights into CMT1 pathogenesis.
• Progress in exploring therapeutic targets and interventions, including clinical trials.

Conclusions:

• Cellular and animal models are instrumental in advancing potential CMT1 therapies.
• Long-term safety and robust efficacy evaluation are critical for clinical translation.
• The non-linear and progressive nature of CMT clinical phenotypes necessitates careful assessment of treatment outcomes.